However, lack of child-specific medicines is another concern of industry experts.

According to the China Food and Drug Administration, China had around 3,500 drug product categories with less than 60 specifically intended for children, and 90 percent of drugs do not come with children dosage information.

Beijing Children's Hospital pharmaceutical office director, Wang Xiaoling, said "many products do not have child dosages and in some cases adult medication can cause an overdose."

Wang said that infants, especially newborns, were at risk of harm due to incorrect dosages, as their organs were still developing.

From 2011 to 2013, there were 1,098 types of drug products used in pediatric clinics in 15 hospitals, but only 45 were exclusively for children, said Wang, citing the results of a medical survey.

Despite the shortage of child medication, pharmaceutical companies are weary of branching out in to the sector, due to increased costs, approval procedures and other risks associated with producing medicine for infants and children.

In 2014, the National Health and Family Planning Commission together with other five departments issued a guideline to tackle the shortage, vowing more support.

The guideline said that China would streamline the approval procedure; encourage research and clinical tests; and issue favorable pricing policies to support development of child-specific medicines.